GFR Calculator

Introduction

The Glomerular Filtration Rate (GFR) is the gold standard measurement for assessing kidney function. It represents the volume of blood filtered by the glomeruli — the tiny filtering units in the kidneys — per unit of time, typically expressed in milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73m²). A healthy adult typically has a GFR between 90 and 120 mL/min/1.73m², though this value naturally declines with age and varies by individual factors including sex, body size, and ethnicity. GFR testing is one of the most commonly ordered laboratory tests in primary care, alongside complete blood counts and basic metabolic panels.

GFR is critically important because it serves as the primary indicator of overall kidney health and is used to stage chronic kidney disease (CKD). When the kidneys are damaged or functioning poorly, the GFR drops, indicating that the kidneys are not effectively filtering waste products, excess fluids, and electrolytes from the blood. Early detection of reduced GFR is essential because CKD often progresses silently without noticeable symptoms until it reaches advanced stages, at which point treatment options become significantly more limited. The global burden of CKD is substantial, affecting an estimated 850 million people worldwide, and it is the 10th leading cause of death globally. In the United States alone, CKD affects approximately 37 million adults, and the prevalence continues to rise with increasing rates of diabetes, hypertension, and an aging population.

This calculator estimates GFR using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, which is currently the most widely recommended formula by nephrology organizations worldwide, as well as the older MDRD (Modification of Diet in Renal Disease) study equation. The CKD-EPI equation was developed in 2009 and has been shown to be more accurate than the MDRD equation, particularly in individuals with higher GFR values and without kidney disease. The economic burden of CKD is immense, with Medicare spending exceeding $80 billion annually in the United States on kidney disease care, including dialysis and transplantation. Early detection of reduced GFR and timely intervention can dramatically reduce these costs while improving quality of life for millions of patients. Beyond the economic impact, the personal toll of advanced CKD is substantial, with patients experiencing reduced energy levels, dietary restrictions, frequent medical appointments, and the emotional burden of living with a progressive chronic illness. Early detection through routine GFR screening offers the best opportunity to slow or halt disease progression before these consequences develop.

What GFR Measures and Why It Matters

GFR quantifies the volume of plasma that the glomeruli filter per unit of time, providing a direct window into how well the kidneys are performing their primary function of clearing metabolic waste products from the bloodstream. When the kidneys are healthy, they filter approximately 90 to 120 mL of blood per minute for every 1.73 square meters of body surface area — enough to process the entire plasma volume multiple times each day. As kidney function declines, this filtration rate drops, allowing toxins such as urea and creatinine to accumulate in the blood.

In children, GFR estimation requires separate equations and is typically adjusted for body surface area. The Schwartz equation, which incorporates height and creatinine, is the most commonly used pediatric GFR formula. Normal pediatric GFR values reach adult levels by approximately two years of age, after adjusting for body size. The CKD-EPI and MDRD equations should not be used in patients under 18 years old.

The GFR value is the cornerstone of chronic kidney disease (CKD) staging, a classification system established by the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI). [nkf-kdoqi] CKD is divided into five stages based on GFR:

• Stage 1 (GFR ≥ 90): Kidney damage is present, typically indicated by markers such as albuminuria, hematuria, or structural abnormalities on imaging, but filtration function remains normal or high. Early intervention can slow or prevent progression.
• Stage 2 (GFR 60–89): Mild reduction in GFR alongside evidence of kidney damage. At this stage, patients often have no symptoms, but laboratory abnormalities begin to appear.
• Stage 3 (GFR 30–59): Moderate reduction. This stage is subdivided into 3a (45–59) and 3b (30–44). Complications such as anemia, bone mineral disorders, and hypertension become more common. Referral to a nephrologist is recommended.
• Stage 4 (GFR 15–29): Severe reduction. Patients typically experience symptoms such as fatigue, fluid retention, and electrolyte imbalances. Preparation for kidney replacement therapy (dialysis or transplant) should begin.
• Stage 5 (GFR below 15): Kidney failure, also called end-stage renal disease (ESRD). Dialysis or a kidney transplant is necessary to sustain life.

Beyond filtration, the kidneys perform essential regulatory functions that depend on adequate GFR. They maintain electrolyte balance by controlling sodium, potassium, and calcium levels. They regulate blood pressure through the renin-angiotensin-aldosterone system. They produce erythropoietin, which stimulates red blood cell production. They activate vitamin D for bone health. When GFR declines, all of these functions become impaired, which is why CKD affects so many organ systems — patients commonly develop anemia, bone disease, hypertension, and electrolyte disorders.

The reason GFR monitoring is so critical lies in the silent nature of early kidney disease. Most people with stage 1 or 2 CKD experience no symptoms — no pain, no visible warning signs. By the time symptoms such as swelling in the legs, shortness of breath, or persistent fatigue appear, kidney function has often already fallen below 30 mL/min. Routine GFR screening through a simple blood test is the only reliable way to catch kidney disease early, when interventions such as blood pressure control, ACE inhibitor therapy, and dietary modification can still meaningfully slow progression. Given that approximately 37 million adults in the United States alone have CKD, and most are unaware of it, understanding and monitoring GFR is one of the most impactful steps you can take for long-term health.

Clinical practice guidelines recommend GFR screening at least annually for individuals with diabetes, hypertension, cardiovascular disease, a family history of kidney disease, or age over 60. Screening should include both a serum creatinine test for eGFR and a urine albumin-to-creatinine ratio test. Earlier detection through routine screening allows for timely intervention that can reduce the risk of progression to kidney failure by 30 to 50 percent in some populations. For individuals without risk factors, screening every one to two years starting at age 40 provides a reasonable baseline for comparison over time. Public health organizations emphasize that knowing your GFR is as important as knowing your blood pressure or cholesterol level, since CKD is one of the most common yet most underdiagnosed conditions worldwide. The CDC estimates that 9 in 10 adults with reduced kidney function do not know they have it, making routine GFR screening one of the most impactful and cost-effective preventive health measures available. A key concept to understand is that GFR trends over time are far more informative than any single measurement. A gradual decline of 2 to 3 mL per minute per year may represent expected aging, while a steeper decline of more than 5 mL per minute per year warrants prompt investigation for an underlying treatable cause of kidney function loss.

How to Use

Using the GFR Calculator is straightforward and requires only a few inputs:

1. Enter Your Age: Input your age in years. GFR naturally declines with age due to normal physiological changes in kidney structure and function. Age is a critical variable in all GFR estimation equations.
2. Enter Your Serum Creatinine Level: Input your most recent serum creatinine measurement in milligrams per deciliter (mg/dL). Creatinine is a waste product generated from muscle metabolism and is filtered by the kidneys. Higher creatinine levels generally indicate lower kidney function. For reference, normal serum creatinine ranges are approximately 0.7–1.3 mg/dL for adult males and 0.6–1.1 mg/dL for adult females.
3. Select Your Gender: Choose between Male or Female. Gender affects GFR estimation because average muscle mass and creatinine production differ between males and females. Males typically produce more creatinine due to greater muscle mass, which is why gender-specific coefficients are applied in the formulas.
4. Review Your Results: The calculator will display your estimated GFR value in mL/min/1.73m² along with the corresponding CKD stage classification. Higher values indicate better kidney function. When reviewing your results, pay attention to the specific CKD stage rather than just the numeric value, as the stage classification carries established clinical recommendations for monitoring frequency and treatment targets. If your GFR falls between 60 and 89, note whether you have other markers of kidney damage such as albuminuria, which would determine whether this represents stage 1 or stage 2 CKD.

For the most accurate results, use a recent blood test result for serum creatinine. If your creatinine is reported in micromoles per liter (μmol/L), you can convert it to mg/dL by dividing by 88.4. Understanding the trajectory of your GFR is often more clinically useful than a single result. A patient whose GFR has gradually declined from 90 to 65 over ten years has a different clinical picture from one whose GFR dropped from 90 to 65 over six months. The rate of change helps distinguish chronic disease from acute events and guides the urgency of intervention.

Formulas and Calculations

The GFR Calculator uses two established equations for estimating kidney function from serum creatinine levels.

GFR Formulas and Their Differences

Several equations have been developed over the past decades to estimate GFR from serum creatinine. Understanding their differences helps patients and clinicians interpret results in the proper context.

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration, 2009/2021): This is the current standard recommended by the National Kidney Foundation, Kidney Disease: Improving Global Outcomes (KDIGO), and most major nephrology societies. The CKD-EPI equation was developed from a broader and more representative population than its predecessor, and it is considerably more accurate at GFR values above 60 mL/min/1.73m². The 2021 update removed the race coefficient (see below) and uses age, sex, and creatinine as inputs. Its bias and precision have been validated across diverse populations, including Asian, Black, and Hispanic groups.

MDRD (Modification of Diet in Renal Disease, 1999): Developed using data from mostly Caucasian patients with established CKD, the MDRD equation was the clinical standard for over a decade. Its main limitation is a systematic underestimation of GFR in individuals with normal or near-normal kidney function (GFR > 60 mL/min/1.73m²), leading to a higher false-positive rate for CKD. For example, a young healthy adult with a true GFR of 100 mL/min might receive an MDRD estimate of only 75 mL/min — incorrectly suggesting stage 2 CKD. The MDRD equation remains in widespread use because of its familiarity and long clinical track record.

Cockcroft-Gault (1976): This older equation differs from CKD-EPI and MDRD in that it uses actual body weight and is not normalized to a standard body surface area. It was developed before the standardization of serum creatinine assays, and its results can differ substantially from CKD-EPI or MDRD. Cockcroft-Gault tends to overestimate GFR in obese individuals and underestimate it in those with low muscle mass. Most modern guidelines no longer recommend its use for estimating GFR, though it is still used in some pharmacokinetic studies for drug dosing.

All three equations share a fundamental limitation — they depend on serum creatinine, which is an imperfect filtration marker. Creatinine is not only filtered by the glomerulus but also secreted by the proximal tubule, meaning creatinine clearance systematically overestimates true GFR. In healthy individuals, tubular secretion accounts for roughly 10 to 20 percent of creatinine excretion. As GFR declines, the proportion of secreted creatinine increases, so the overestimation grows larger in advanced disease. This is why cystatin C or measured clearance may be preferred for accurate assessment in stage 4 and 5 CKD.

The practical difference between these formulas can be significant for individual patients. Consider a 45-year-old female with a creatinine of 1.0 mg/dL: CKD-EPI might estimate her GFR at approximately 90 mL/min/1.73m², MDRD at 75 mL/min/1.73m², and Cockcroft-Gault at 82 mL/min if she weighs 70 kg. The choice of formula directly influences whether she is classified as normal (stage 1) or mildly reduced (stage 2), with potential implications for medication dosing and clinical follow-up.

The Race Coefficient Controversy and the 2021 Update: For years, GFR estimating equations included a separate coefficient for Black patients (typically a multiplier of 1.21), based on observations that Black individuals tend to have higher average serum creatinine levels at the same measured GFR. However, this approach has been widely criticized as perpetuating racial bias in medicine. Race is a social construct, not a biological variable, and the coefficient was derived from limited data. In 2021, the CKD-EPI equation was updated to remove the race coefficient entirely, creating a single race-free equation for all patients. The NKF and ASN jointly recommended this change. The updated equation performs well across populations, though ongoing research continues to refine its accuracy in specific ethnic groups.

International Guidelines: The KDIGO 2024 clinical practice guidelines recommend the CKD-EPI 2021 equation as the preferred method for initial GFR estimation in adults. The UK's National Institute for Health and Care Excellence similarly endorses CKD-EPI as the primary equation and recommends against using Cockcroft-Gault for GFR estimation. In Australia and New Zealand, the CKD-EPI equation is the standard for chronic kidney disease diagnosis and staging. Most European nephrology societies have also adopted the race-free CKD-EPI 2021 equation. Despite this international consensus, the MDRD equation continues to be reported by many laboratories alongside CKD-EPI, particularly in settings where clinical teams have long-standing familiarity with its interpretation.

Reference Tables

Additional Diagnostic Tests for Kidney Health

GFR alone does not tell the complete story of kidney health. Clinicians use a battery of complementary tests to build a full picture of kidney function and damage.

Urine Albumin-to-Creatinine Ratio: This test measures the amount of albumin in the urine relative to creatinine. Albumin in the urine, called albuminuria, is an early sign of kidney damage that can appear before GFR begins to decline. A UACR below 30 mg per gram is normal. Values between 30 and 300 mg per gram indicate moderately increased albuminuria, and values above 300 mg per gram represent severely increased albuminuria. Even when GFR is normal, an elevated UACR is a strong predictor of CKD progression, cardiovascular risk, and overall mortality. The combination of GFR and UACR provides a more complete risk assessment than either marker alone.

Blood Urea Nitrogen: Urea is another waste product filtered by the kidneys. The BUN level complements creatinine measurements for assessing kidney function and hydration status. The BUN-to-creatinine ratio helps distinguish prerenal causes of creatinine elevation, such as dehydration or heart failure, from intrinsic kidney damage. A ratio above 20 to 1 typically suggests reduced renal blood flow rather than primary kidney disease, guiding clinicians toward different diagnostic and treatment pathways.

Renal Ultrasound: Imaging of the kidneys with ultrasound assesses kidney size, structure, and the presence of obstructions, cysts, or tumors. Small, shrunken kidneys suggest chronic, long-standing disease, whereas normal-sized or enlarged kidneys may indicate acute disease, diabetic nephropathy, or polycystic kidney disease. Doppler ultrasound can also evaluate blood flow through the renal arteries, helping identify renovascular causes of hypertension and reduced GFR.

Kidney Biopsy: When the underlying cause of kidney disease remains unclear after blood tests, urine tests, and imaging, a kidney biopsy may be performed. A small tissue sample is obtained with a needle and examined under a microscope. Biopsy can diagnose specific glomerular diseases such as IgA nephropathy, membranous nephropathy, or lupus nephritis. The results guide treatment decisions that can preserve remaining kidney function.

When to Order Additional Tests: Any patient with a confirmed eGFR below 60 mL/min/1.73m² for three or more months should undergo at minimum a UACR test, blood pressure measurement, and a basic metabolic panel including electrolytes and BUN. If GFR is declining by more than 5 mL/min/1.73m² per year, further investigation including renal ultrasound is warranted. Rapid decline, the presence of significant proteinuria, or concurrent autoimmune symptoms may prompt earlier referral for biopsy. The combination of GFR trend, UACR, and imaging provides the most complete picture of kidney health status. Serial measurements of UACR are particularly valuable because changes in albumin excretion often precede GFR declines by months or years, making it an early warning system for progressive kidney damage. A consistently rising UACR, even with stable GFR, warrants closer monitoring and more aggressive risk factor management.

Cystatin C Testing as a Complementary Tool

Cystatin C is an alternative filtration marker that offers several advantages over creatinine. It is produced at a constant rate by all nucleated cells and is freely filtered by the glomerulus, then reabsorbed and metabolized in the proximal tubule. Unlike creatinine, cystatin C is not affected by muscle mass, age, sex, or dietary protein intake, making it particularly valuable in patient populations where creatinine-based estimates are known to be less reliable.

The CKD-EPI cystatin C equation provides a GFR estimate that can be used alone or in combination with the creatinine-based equation. The combined creatinine-cystatin C equation is generally considered the most accurate eGFR method currently available. It is especially useful in elderly patients with low muscle mass, in individuals with unusual body composition, in those with chronic liver disease where creatinine production is reduced, and in patients being evaluated as potential living kidney donors where precision matters most. When creatinine-based and cystatin C-based estimates agree closely, confidence in the reported GFR is high. When they disagree, it may indicate non-GFR determinants affecting one or both markers, prompting further investigation.

Cystatin C testing is not yet universal because the test is more expensive than creatinine and not all laboratories offer it. However, its use is growing, and many guidelines now recommend confirmatory cystatin C measurement when creatinine-based eGFR is borderline or when clinical suspicion does not match the reported eGFR value. The additional cost is typically justified in complex clinical scenarios where accurate GFR assessment directly influences major treatment decisions such as chemotherapy dosing, contrast dye administration, or transplantation evaluation. As laboratory automation improves, the cost of cystatin C testing continues to decrease, and it is expected that routine use will become more widespread in the coming years. Wider adoption of cystatin C testing could significantly improve the accuracy of GFR estimation in populations where creatinine has known limitations, reducing misclassification and enabling more personalized clinical decision making for patients at all stages of kidney disease.

Limitations

1. Estimation, Not Measurement: This calculator provides an estimate of GFR based on mathematical equations, not a direct measurement. Measured GFR (mGFR) using techniques like inulin clearance or iothalamate clearance is more accurate but is complex, expensive, and not routinely performed in clinical settings.
2. Creatinine Limitations: The estimates rely on serum creatinine, which can be influenced by factors unrelated to kidney function. Individuals with high muscle mass (athletes, bodybuilders) may have elevated creatinine levels despite normal kidney function. Conversely, elderly individuals or those with low muscle mass (cachexia, amputation) may have deceptively low creatinine levels despite significant kidney impairment.
3. Dietary Effects: High-protein diets, creatine supplementation, and certain foods (cooked meat) can temporarily elevate serum creatinine, potentially underestimating GFR. Similarly, very low protein diets or severe liver disease may lower creatinine independent of kidney function.
4. Race and Ethnicity: Some GFR estimating equations historically included race-based coefficients, which has been controversial. The CKD-EPI 2021 equation has removed the race coefficient, but accuracy may still vary across different population groups.
5. Acute Kidney Injury: These equations are designed to estimate GFR in steady-state conditions and may not accurately reflect rapidly changing kidney function in acute kidney injury (AKI) settings.
6. Body Size and Composition: The equations normalize results to a standard body surface area of 1.73m², which may not accurately reflect kidney function in individuals who are significantly underweight, obese, or have unusual body composition.
7. Drugs and Substances: Certain medications (trimethoprim, cimetidine) can block creatinine secretion in the kidney tubules, artificially elevating serum creatinine and underestimating GFR.
8. Pregnancy: GFR naturally increases by approximately 50% during pregnancy. These equations have not been validated for use in pregnant women and should not be used for that population.
9. Pediatric Populations: The CKD-EPI and MDRD equations were developed for adults aged 18 and older. In children, GFR estimation requires separate pediatric equations such as the Schwartz formula, which uses height and creatinine. Using adult equations in pediatric patients produces unreliable results.
10. Single Kidney and Donor Populations: Individuals with a single kidney, whether from congenital causes or surgical donation, typically have a GFR that is 25 to 40 percent lower than their two-kidney baseline. Standard estimating equations were designed for two-kidney physiology and may not perfectly capture function in this growing population of living kidney donors.
11. Creatinine Assay Standardization: GFR estimating equations were developed using specific creatinine assay methods. Although modern laboratories use standardized isotope dilution mass spectrometry (IDMS) methods, historical data or laboratories using older assays may produce different creatinine values, leading to systematic bias in GFR estimates. Patients tested at different laboratories may see slightly different results for the same true kidney function.

Factors That Affect GFR Accuracy

The accuracy of a creatinine-based GFR estimate depends on the assumption that serum creatinine is produced at a steady rate and reflects stable kidney function. In practice, several physiological and pathological factors can distort this relationship.

Acute Kidney Injury (AKI): The equations presented here assume steady-state conditions. In AKI — where kidney function is deteriorating over hours or days — serum creatinine lags behind the actual GFR drop. A patient whose GFR has fallen from 90 to 20 mL/min over 24 hours might still show a relatively modest creatinine elevation, giving a falsely reassuring GFR estimate. Serial measurements and urine output monitoring are essential in acute settings.

Pregnancy: During a normal pregnancy, GFR increases by approximately 50 percent due to increased renal blood flow and glomerular filtration pressure. A pregnant woman with a measured GFR of 120 mL/min may actually have a non-pregnant baseline closer to 80 mL/min. Standard estimating equations have not been validated in pregnancy and should not be relied upon for this population. Clinicians typically monitor other markers such as urine protein and blood pressure instead.

Muscle Mass: Creatinine is produced from creatine phosphate in skeletal muscle, so muscle mass directly influences creatinine production. Elite athletes and bodybuilders may have mildly elevated creatinine despite normal kidney function, leading to an underestimated GFR. Conversely, elderly individuals, people with amputations, those with cachexia from cancer or advanced illness, and people on vegetarian diets all produce less creatinine. Their GFR estimates may appear falsely reassuring — a serum creatinine in the normal range can hide substantial kidney impairment when muscle mass is low.

Medications: Several drugs interfere with creatinine handling or directly affect kidney function. Trimethoprim (an antibiotic) and cimetidine (an acid reducer) competitively block tubular creatinine secretion, raising serum creatinine by about 10 to 20 percent without changing true GFR. NSAIDs such as ibuprofen and naproxen can reduce GFR by constricting afferent renal arterioles, particularly in volume-depleted patients or those with pre-existing kidney disease. ACE inhibitors may cause a mild, stable rise in creatinine that does not reflect progressive kidney damage.

Diet: A large cooked meat meal can transiently raise serum creatinine by up to 30 percent within hours. Creatine supplements and high-protein diets produce similar effects. For this reason, patients are sometimes advised to avoid heavy protein intake before blood tests. Conversely, a vegetarian diet produces lower baseline creatinine levels, potentially causing GFR overestimation. Fasting or very low calorie diets can also elevate creatinine because of increased protein catabolism, creating a complex relationship between nutritional status and kidney function assessment.

Hydration Status: Dehydration reduces renal blood flow and can cause a transient rise in serum creatinine. When a dehydrated patient is rehydrated with intravenous fluids, the creatinine level often drops within 24 to 48 hours as renal perfusion is restored. This is why repeat testing after adequate hydration is important before concluding that a reduced GFR represents chronic disease.

Exercise and Physical Activity: Strenuous exercise, particularly resistance training and high-intensity interval workouts, can cause a temporary increase in serum creatinine due to muscle microtrauma and increased protein turnover. This effect is usually mild and resolves within 24 to 72 hours with rest. Endurance athletes may show slightly elevated baseline creatinine due to higher muscle mass. For this reason, it is advisable to avoid intense physical activity for at least 24 hours before a blood test for creatinine. After major surgeries or traumatic muscle injury, creatinine can be significantly elevated due to rhabdomyolysis, which directly damages muscle fibers and releases large amounts of myoglobin and creatinine into the bloodstream.

Age-Related Decline: GFR naturally declines with age even in healthy individuals without kidney disease. This is due to glomerulosclerosis, decreased nephron mass, and reduced renal blood flow. A commonly cited approximation is that GFR decreases by roughly 1 mL/min/1.73m² per year after age 40. An 80-year-old with a GFR of 55 mL/min may have age-appropriate function, while the same number in a 40-year-old would indicate significant impairment. Laboratories report GFR in the same range regardless of age, so clinical interpretation must account for normal age-related changes. The CKD-EPI and MDRD equations both include age as a variable, which partially adjusts for this effect, but they cannot fully separate pathological decline from physiological aging.

Kidney Transplant Considerations: In kidney transplant recipients, GFR monitoring is especially important because transplant function can decline gradually due to chronic rejection, calcineurin inhibitor toxicity, or recurrent disease. Transplant nephrologists typically track eGFR closely and use combined creatinine-cystatin C equations for greater accuracy in this population. A decline in GFR after transplant may trigger changes in immunosuppressive medication regimens or prompt a biopsy to evaluate for rejection. Living kidney donors also require lifelong GFR monitoring, as their remaining kidney undergoes hyperfiltration and compensatory hypertrophy, which can accelerate function loss in some individuals.

Timing of Blood Draw: Serum creatinine levels can vary throughout the day due to diurnal rhythms, physical activity, and dietary intake. Morning blood draws generally provide the most standardized results because creatinine production is lowest after overnight fasting and rest. If you have multiple GFR tests over time, they will be most comparable if drawn at approximately the same time of day and under similar conditions. Consistent testing conditions reduce measurement variability and help your doctor accurately assess whether your kidney function is truly stable, declining, or improving over time.

Practical Tips

1. Consult Your Doctor: Always discuss your GFR results with a healthcare professional. GFR is just one piece of the puzzle — actual kidney health assessment also considers urine tests, imaging, blood pressure, and clinical history. Your doctor may recommend additional testing such as urine albumin-to-creatinine ratio (ACR) or imaging studies.
2. Use Recent Lab Results: For the most accurate estimate, use your most recent serum creatinine measurement. Kidney function can change over time based on hydration, medications, and other factors. Creatinine levels can fluctuate day to day.
3. Consider Multiple Estimates: Some clinicians recommend using both the CKD-EPI and MDRD equations together, as well as cystatin C-based estimates, to get a more complete picture of kidney function. Discrepancies between estimates may warrant further investigation.
4. Track Trends: A single GFR number provides limited information. Tracking your GFR over time (along with urine albumin and other markers) is more informative for assessing disease progression. Regular monitoring allows early detection of worsening kidney function.
5. Know Your Numbers: Understanding your GFR helps you make informed decisions about your health, follow appropriate monitoring schedules, and communicate effectively with your healthcare provider. Keep a record of your GFR results over time.
6. Medication Adjustments: Many medications require dose adjustments based on kidney function. If your GFR is below 60 mL/min/1.73m², inform your healthcare provider so they can review your medications and make appropriate adjustments.
7. Understand Creatinine Sample Collection: Serum creatinine is typically measured from a standard venous blood draw. For most people, no special preparation is needed, though it is advisable to schedule the test in the morning before a heavy meal. Avoid intensive exercise or weightlifting for 24 hours before the test, as muscle breakdown from strenuous activity can transiently raise creatinine. If you take creatine supplements, ask your doctor whether you should pause them before testing.
8. What to Do If Your GFR Is Low: A single low GFR result does not necessarily mean chronic kidney disease. If your GFR falls below 60 mL/min/1.73m², your doctor will typically repeat the test within two to three months to confirm persistence, rule out transient factors such as dehydration or medication effects, and order a urine albumin-to-creatinine ratio test. In the meantime, stay well hydrated, avoid NSAIDs such as ibuprofen, and check your blood pressure regularly.
9. When to See a Nephrologist: The National Kidney Foundation recommends nephrology referral when GFR remains below 60 mL/min/1.73m² for three or more months, or when the urine albumin-to-creatinine ratio exceeds 30 mg/g. Earlier referral is appropriate if kidney function is declining rapidly, blood pressure is difficult to control, or there is significant hematuria or structural kidney abnormalities. A nephrologist can help identify the underlying cause, slow disease progression, and manage complications such as anemia and mineral metabolism disorders.
10. Lifestyle Changes That Support Kidney Health: Maintaining a blood pressure below 130/80 mmHg is one of the most effective ways to slow CKD progression. A diet low in sodium (under 2,300 mg per day), moderate in protein (0.8 g per kg of body weight), and rich in fruits and vegetables supports kidney function. Avoiding tobacco, limiting alcohol, staying physically active, and maintaining a healthy weight are also important. If you have diabetes, careful blood sugar management is essential — diabetic nephropathy is the leading cause of kidney failure worldwide.
11. Dietary Protein and Sodium Management: For individuals with GFR below 60 mL/min/1.73m², reducing dietary protein to approximately 0.8 grams per kilogram of body weight per day reduces the workload on the kidneys and can slow disease progression. Equally important is limiting sodium intake to under 2,300 mg per day, which helps control blood pressure and reduces proteinuria. A renal dietitian can provide personalized meal planning tailored to your stage of kidney disease.
12. Medication Safety and NSAID Avoidance: Many over-the-counter pain relievers, particularly nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, can reduce blood flow to the kidneys and worsen GFR. Patients with known CKD or GFR below 60 should avoid NSAIDs entirely and use acetaminophen for pain relief instead. Always consult a healthcare provider before starting any new medication, including herbal supplements, as some can affect kidney function.
13. Schedule Regular Kidney Function Checks: If you have diabetes, hypertension, or a family history of kidney disease, schedule a comprehensive kidney function assessment annually. This should include eGFR, UACR, blood pressure measurement, and basic electrolytes. For individuals over 60, screening every one to two years is recommended even in the absence of known risk factors. Keeping a personal log of your eGFR and UACR results helps you and your doctor track trends and detect meaningful changes early.
14. Understand Dialysis Planning Thresholds: When GFR falls below 30 mL/min/1.73m², it is time to begin discussing kidney replacement therapy options with your healthcare team. This includes education about hemodialysis, peritoneal dialysis, and kidney transplantation. Planning for vascular access placement or peritoneal catheter insertion takes time and is associated with better outcomes when done electively rather than emergently. Knowing your GFR trajectory helps you and your doctor prepare well in advance for these decisions, avoiding the need for urgent dialysis initiation.
15. Ask About Kidney Protective Medications: Several classes of medications have been shown to slow the progression of CKD independent of their effects on blood pressure. These include ACE inhibitors, angiotensin receptor blockers (ARBs), and more recently SGLT2 inhibitors such as dapagliflozin and empagliflozin. If you have CKD with albuminuria, ask your healthcare provider whether these medications are appropriate for you. Early initiation of kidney protective therapy can add years of preserved kidney function. These medications work by reducing intraglomerular pressure, decreasing proteinuria, and providing anti-inflammatory and antifibrotic effects within the kidney tissue beyond what blood pressure control alone achieves.

Frequently Asked Questions

What is a normal GFR?

A normal GFR is generally considered to be 90 mL/min/1.73m² or higher, though GFR naturally declines with age. For a healthy young adult, typical values range from 90–120 mL/min/1.73m².

Can GFR improve?

In some cases, yes. Certain causes of kidney function decline (such as dehydration, urinary tract obstruction, or medication effects) are reversible with appropriate treatment. However, in chronic kidney disease, GFR loss is typically progressive.

What is the difference between CKD-EPI and MDRD?

CKD-EPI is a newer equation generally considered more accurate, especially at higher GFR values. MDRD was the standard for many years but tends to underestimate GFR in people with near-normal kidney function. The CKD-EPI equation is now recommended by most nephrology guidelines.

Do I need to fast before the test?

No fasting is required for a serum creatinine test. However, you should avoid eating large amounts of cooked meat before the test, as it can temporarily increase creatinine levels.

At what GFR level do symptoms appear?

Most people with CKD stages 1–3 do not experience noticeable symptoms. Symptoms such as fatigue, swelling, changes in urination, and shortness of breath typically do not appear until stage 4 or 5, when kidney function is severely reduced.

What is a cystatin C test and how is it different from creatinine?

Cystatin C is a protein produced by all nucleated cells and is filtered by the kidneys much like creatinine. Unlike creatinine, cystatin C is not affected by muscle mass, age, gender, or diet. The cystatin C-based GFR estimate can be more accurate in populations where creatinine is unreliable, including the elderly, people with very high or low muscle mass, and those with chronic liver disease. However, it is more expensive and less widely available than the standard creatinine test.

How does dialysis relate to GFR?

Dialysis, whether hemodialysis or peritoneal dialysis, is a life-sustaining treatment that artificially performs the filtering function of the kidneys. It is typically initiated when GFR falls below 15 mL/min/1.73m² (stage 5 CKD), though the exact timing depends on the patient's symptoms, nutritional status, and electrolyte balance. Dialysis does not restore GFR — it replaces the filtration function that the kidneys can no longer perform. Some patients may eventually be candidates for a kidney transplant, which can restore normal or near-normal GFR.

What is the difference between eGFR and measured GFR?

Measured GFR (mGFR) is the true filtration rate determined by measuring the clearance of an exogenous filtration marker such as inulin, iothalamate, or iohexol after intravenous infusion. It is the gold standard but is expensive, time-consuming, and rarely performed outside of research settings. Estimated GFR (eGFR) is derived from equations using endogenous markers like creatinine or cystatin C. While convenient and inexpensive, eGFR carries a margin of error of roughly 10 to 15 percent. For most clinical decision-making, eGFR is sufficiently accurate, but when precise kidney function measurement is critical — such as for living kidney donor evaluation — mGFR may be preferred.

What is a normal GFR for my age?

In young, healthy adults between the ages of 20 and 40, normal GFR is typically above 90 mL/min/1.73m². GFR declines with age: an average 60-year-old might have a GFR around 85 mL/min, and an average 80-year-old around 65 mL/min. However, even in older adults, a GFR below 60 mL/min/1.73m² warrants further evaluation, as it may indicate kidney disease above and beyond normal aging. Laboratories report GFR without age adjustment, so discuss your specific result with your doctor.

How do diabetes and hypertension affect GFR?

Diabetes and hypertension are the two leading causes of chronic kidney disease. High blood glucose damages the glomeruli over time, causing thickening of the glomerular basement membrane and increased filtration pressure, a condition called diabetic nephropathy. Hypertension damages the small blood vessels within the kidneys, reducing renal blood flow and promoting glomerulosclerosis. Together or individually, they lead to a progressive decline in GFR. Tight blood sugar control (A1C under 7 percent) and blood pressure control (below 130/80 mmHg) are the most effective strategies to slow or prevent this decline.

References

1. [1]Levey, A.S., et al. (2009). "A New Equation to Estimate Glomerular Filtration Rate." *Annals of Internal Medicine*, 150(9), 604–612.
2. [2]Levey, A.S., et al. (1999). "A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation." *Annals of Internal Medicine*, 130(6), 461–470.
3. [3]National Kidney Foundation. (2002). "K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease." *American Journal of Kidney Diseases*, 39(2), S1–S266.
4. [4]Inker, L.A., et al. (2021). "New GFR and Albuminuria Equations for CKD." *American Journal of Kidney Diseases*, 77(6), 800–816.
5. [5]National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2023). "Your Kidneys & How They Work."
6. [6]Stevens, L.A., et al. (2006). "Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate." *New England Journal of Medicine*, 354(23), 2473–2483.